Boston Scientific (BSX)
Salud / Dispositivos médicos
Boston Scientific leads two high-growth categories — left atrial appendage closure (WATCHMAN) and pulsed field ablation (FARAPULSE) — behind a moat of patents, regulatory barriers, and clinical switching costs. The stock lost more than half its value from its high for the year after the company cut its 2026 guidance, and at 16× on adjusted earnings it trades below the band of its medical technology peers: It trades close to intrinsic value, far from the required margin of safety.
- Price
- $49.84
- Intrinsic value (5y, base)
- $79
- Total annual return (5y)
- 9.7%
- Status (nominal)
- Fairly valued
- Margin of safety
- +21%
The essentials
- The company cut its 2026 guidance — revenue growth of 6.5% to 8.5%, down from 10.5% to 11.5%, and adjusted earnings per share of $3.34 to $3.41 — on slowing growth and increased competition in WATCHMAN and electrophysiology. This analysis's growth path starts from that guidance, not from the historical trajectory.
- Even with the cut guidance, adjusted earnings still grow at a low double-digit rate, and the market values it at 16×: below the 16-22x band at which Abbott, Medtronic, and Stryker are valued.
- The pending acquisition of Penumbra ($14.8 billion, with about $11.0 billion of new debt) is excluded from the base case: it has not closed, faces a second request for information from antitrust authorities, and the company itself states it will be dilutive in the first full year.
Intrinsic value — two valuation methods
By both methods, the value today (DCF $97 · Multiples $63) exceeds the market price ($50).
Pillars of the analysis
The verdict — today vs 5 years
Today — fairly valued: at $50 trades ~21.4% below its value discounted to today (~$63); the discount is positive but does not reach the margin of safety we require (≥38%).
At 5 years — En valor: the target price ($79) plus dividends yield between the 4% floor and the 10% average return — a reasonable return, though without the margin of a great investment.
The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$39.
Thesis
The business
A medical device manufacturer with defensible leadership positions protected by patents, regulatory barriers, and clinical switching costs in implantables. Adjusted earnings grew from $2.05 to $2.51 and to $3.06 per share between 2023 and 2025, with the adjusted net margin expanding from 21.1% to 22.8%. Operating quality is not in question; what changed is the pace.
The valuation
It is valued on P/E over the adjusted earnings that the company itself reconciles, the same metric and band (16-22x) used to value Abbott, Medtronic, and Stryker. GAAP earnings are not useful here: the gap versus adjusted earnings is almost entirely non-cash amortization from a dozen acquisitions. The terminal multiple is set at 17x, in the low half of the band, because the competition that forced the guidance cut is real and it is not yet known where it stabilizes. The 5-year value is $79, implying an annual +10% at the market price.
The margin of safety
It trades close to intrinsic value, far from the required margin of safety. The stock lost more than half its value from its high for the year and trades at 16× on adjusted earnings, against a peer band of 16-22x. What is being paid today does not require a reacceleration: the base case uses the company's own guidance, already cut, and it still leaves room to run. The verdict is Fairly valued.
What to watch
The gauge is WATCHMAN and electrophysiology: if competition keeps eroding growth beyond what the guidance already acknowledges, this analysis's growth path breaks down and the multiple offers no protection. Second, the Penumbra acquisition: whether or not it closes, if it does it adds about $11.0 billion of new debt to a balance sheet that already carries $11,436 million and is dilutive in the first year. Third, that the guidance cut does not repeat: two consecutive cuts would stop being an adjustment and become a trend.
Educational / informational. Does not constitute investment advice.